Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4798692
Max Phase: Preclinical
Molecular Formula: C17H16F2NO4P
Molecular Weight: 367.29
Molecule Type: Unknown
Associated Items:
ID: ALA4798692
Max Phase: Preclinical
Molecular Formula: C17H16F2NO4P
Molecular Weight: 367.29
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CCP(=O)(OC)c1ccc2oc(-c3cccc(OC(F)F)c3)nc2c1
Standard InChI: InChI=1S/C17H16F2NO4P/c1-3-25(21,22-2)13-7-8-15-14(10-13)20-16(24-15)11-5-4-6-12(9-11)23-17(18)19/h4-10,17H,3H2,1-2H3
Standard InChI Key: QGRJSFQOKHUSCT-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 367.29 | Molecular Weight (Monoisotopic): 367.0785 | AlogP: 4.67 | #Rotatable Bonds: 6 |
Polar Surface Area: 61.56 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 0 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: | CX LogP: 4.05 | CX LogD: 4.05 |
Aromatic Rings: 3 | Heavy Atoms: 25 | QED Weighted: 0.59 | Np Likeness Score: -1.40 |
1. Chatzopoulou M,Emer E,Lecci C,Rowley JA,Casagrande AS,Moir L,Squire SE,Davies SG,Harriman S,Wynne GM,Wilson FX,Davies KE,Russell AJ. (2020) Decreasing HepG2 Cytotoxicity by Lowering the Lipophilicity of Benzo[d]oxazolephosphinate Ester Utrophin Modulators., 11 (12): [PMID:33335663] [10.1021/acsmedchemlett.0c00405] |
Source(1):